Concepedia

Author

Raquel von Schumann

Ludwig-Maximilians-Universität München

Also Known As

R Von Schumann, R von Schumann, R. von Schumann, Raquel Von Schumann, Raquel von Schumann, Raquel von Schumann

35

Publications

765

Citations

12

H-Index

14

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenWaldkrankenhaus Protestant HospitalDeutsches Archäologisches Institut, ZentraleKliniken Essen-MitteMedizinische Hochschule Hannover
RV

About

Raquel von Schumann is an author at Ludwig-Maximilians-Universität München specializing in breast cancer, cancer therapeutics, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

228

2

Pharmacology

3

3

41

3

Health Sciences

1

1

76

4

Pathology

1

1

111

5

Cancer Epidemiology

1

1

11

Raquel von Schumann

×

15

Publications

731

Citations

12

H-Index

YearCitations

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck, Oleg Gluz, Matthias Christgen,

Journal of Clinical Oncology

2017

143

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Oleg Gluz, Ulrike Nitz, Cornelia Liedtke,

JNCI Journal of the National Cancer Institute

2017

122

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi,

Annals of Oncology

2019

111

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi,

Annals of Oncology

2021

83

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser,

The Lancet Oncology

2022

76

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

Rachel Wuerstlein, Karl Sotlar, Oleg Gluz,

Current Medical Research and Opinion

2016

33

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

Nadia Harbeck, Ulrike Nitz, Matthias Christgen,

Journal of Clinical Oncology

2023

33

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/<i>ERBB2</i>-Positive Early Breast Cancer

Oleg Gluz, Ulrike Nitz, Matthias Christgen,

JAMA Oncology

2023

30

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Monika Graeser, Simone Schrading, Oleg Gluz,

Breast Cancer Research

2021

21

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Nadia Harbeck, Raquel von Schumann, Ronald Kates,

Cancers

2021

17

Page 1